About LumaBridge
LumaBridge is a company based in San Antonio (United States) founded in 2000 by George Peoples was acquired by Avance Clinical in January 2026. LumaBridge offers products and services including Clinical Trial Consultation, Regulatory Affairs Services, and Data Management Services. LumaBridge operates in a competitive market with competitors including Orakl Oncology, Oncodesign, Lytica Therapeutics, Orange Grove Bio LLC and Axios Biosciences, among others.
- Headquarter San Antonio, United States
- Founders George Peoples
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lumabridge, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Avance Clinical
& 1 more
-
Employee Count
Not available
-
Acquired by
Avance Clinical
(Jan 07, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LumaBridge
LumaBridge offers a comprehensive portfolio of products and services, including Clinical Trial Consultation, Regulatory Affairs Services, and Data Management Services.
Guides biopharma on trial design and development strategies.
Assists in navigating FDA procedures and regulatory requirements.
Handles clinical data management and biostatistics for trials.
People of LumaBridge
Unlock access to complete
Funding Insights of LumaBridge
Investors in LumaBridge
LumaBridge has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Avance Clinical and Summit Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Summit Partners is recognized as a growth equity investment firm.
|
Locked | Locked | Locked | |
|
Clinical development services are provided to pharmaceutical clients worldwide.
|
Locked | Locked | Locked |
Investor details for LumaBridge
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LumaBridge
Investment portfolio details for LumaBridge
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LumaBridge
Detailed financials for LumaBridge
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lumabridge Comparisons
Peer comparison for LumaBridge
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LumaBridge
LumaBridge operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orakl Oncology, Oncodesign, Lytica Therapeutics, Orange Grove Bio LLC and Axios Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.
|
|
| Locked | Locked | Locked |
Preclinical assessment services for anti-cancer therapies are provided.
|
|
| Locked | Locked | Locked |
Therapeutic drugs are developed for medical applications.
|
|
| Locked | Locked | Locked |
Provider of preclinical development services
|
|
| Locked | Locked | Locked |
Creates innovative platforms for anti-cancer drug development.
|
Detailed competitors of LumaBridge
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lumabridge
Complete news archive for LumaBridge
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LumaBridge
LumaBridge was founded in 2000 and raised its 1st funding round 22 years after it was founded.
LumaBridge is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Dave Boyle is the current CEO of LumaBridge.
LumaBridge was founded in 2000 and is based in San Antonio, United States. Oncology-focused clinical research organization services are offered, including clinical trial design and execution for emerging biopharma companies. Regulatory affairs and data management support are provided as part of strategic development partnerships. Academic, scientific, and commercial perspectives are integrated to advance immunotherapies in the oncology sector.
LumaBridge's top competitors include Oncodesign, Orakl Oncology and Lytica Therapeutics.
LumaBridge offers Clinical Trial Consultation, Regulatory Affairs Services, and Data Management Services.
LumaBridge has 2 investors. Key investors include Avance Clinical, and Summit Partners.